XBXinling Bi

Xinling Bi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xinling Bi has a total of 114 co-authors. Here are the top co-authors by number of shared publications:

  • Jun Gu

    Department of Dermatology, Changhai Hospital, Second Military Medical University, Shanghai, China

    5 shared publications
  • Dapeng Cheng

    Department of Dermatology, The First Affiliated Hospital of Naval Medical University, Shanghai, People’s Republic of China

    3 shared publications
  • Zhi Liu

    Department of Dermatology, The First Affiliated Hospital of Naval Medical University, Shanghai, People’s Republic of China

    3 shared publications
  • Zhuo Chen

    Department of Dermatology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, People’s Republic of China

    3 shared publications
  • Qing-Sheng Mi

    Center for Cutaneous Biology and Immunology Research, Department of Dermatology, Henry Ford Health, Detroit, MI 48202, USA

    2 shared publications
  • Xin Zhou

    Department of Dermatology, Changhai Hospital, Naval Medical University, Shanghai, 200433, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Clinical predictors of early treatment response across systemic therapies in psoriasis: a prospective cohort study

    by Didaer Muheyati, Yuxiong Jiang, Zhenquan Xuan, Siqi Li, Lian Cui, Rui Ma, Yukun Wang, Yuye Wang, Tong Liu, Yuanwenke Zhang, et al.

    Psoriasis is a chronic, immune-mediated inflammatory disease affecting approximately 1–3% of the global population and is clinically characterized by erythematous plaques and scaling. Advances in t...


  • Open Access

    Development of a Cutaneous Horn on a Lower Extremity with Granuloma Annulare: A Rare Co-Occurrence

    by Xiaolin Bu, Liwei Feng, Jing Guo, Rongzhu Yu, Xinling Bi

    A 65-year-old Asian male presented with a circular skin lesion on the flexor aspect of the right calf that first appeared at age 13 and gradually expanded peripherally. Six months prior to presentation, a dark brown, horn-like keratotic lesion with a hard texture emerged on the annular lesion, growing progressively without pain or pruritus. The cutaneous horn was surgically excised, and the annular lesion underwent biopsy. Pathological findings revealed abundant mucin in dermal collagen, dense histiocyte infiltration, and focal mild collagen degeneration, confirming a diagnosis of granuloma annulare complicated by a cutaneous horn.

  • Open Access

    IRAK4 Targeting: A Breakthrough Approach to Combat Hidradenitis Suppurativa

    by Hui Zhang, Zhi Liu, Bozhao Qin, Dapeng Cheng, Peisheng Chen, Xinling Bi

    Hidradenitis suppurativa (HS), a chronic inflammatory condition, features recurrent, painful lesions in the perineal area, severely impairing patients’ quality of life. Despite its clinical significance, HS pathogenesis remains incompletely understood, and effective treatments are scarce. Interleukin-1 receptor-associated kinase 4 (IRAK4) is located downstream of IL-1R/TLR in the IL-1R/TLR signaling pathway, which is upstream of the end products of the pathway. IRAK4-targeted drugs can potentially block this pathway, reducing cytokine secretion and alleviating HS symptoms. This paper comprehensively reviews IRAK4 and its family members’ physiological functions, systematically examines the IRAK family’s roles in the IL-1R/TLR pathway, with a focus on IRAK4, analyzes IRAK4’s specific role in HS, strengthening the theoretical basis for using IRAK4-targeted drugs. The text also covers representative drugs of the major biologics currently used in the treatment of HS and describes the IRAK4 inhibitor Zimlovisertib and the IRAK4 degrader KT-474, along with a discussion of the current status of drugs that inhibit IRAK4 in the treatment of HS and the challenges they face.


  • Open Access

    Comprehensive Analysis of Effectiveness and Cost‐Effectiveness of Treatments for Psoriasis Integrating Clinician‐ and Patient‐Reported Outcomes: A Cohort Study From SPEECH

    by Ning Yu, Yu Wang, Lian Cui, Xia Li, Jun Gu, Xinling Bi, Jinhua Xu, Hui Deng, Xin Li, Qiang Wang, et al.

    Effective and cost‐effective management strategies for psoriasis are crucial for clinical decision‐making. In the management of psoriasis, evidence concerning the effectiveness and cost‐effectiveness of therapies from both clinicians’ and patients’ perspectives is vital for clinical decision‐making. To compare the effectiveness and cost‐effectiveness of acitretin, methotrexate, phototherapy, and biologics (adalimumab, ustekinumab, guselkumab, secukinumab, and ixekizumab) in treating chronic plaque psoriasis, we collected the data from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH), an observational, multicenter, and prospective registry. Integrating both clinician‐ and patient‐reported outcomes allows for a comprehensive evaluation of treatment impacts, capturing clinical disease improvements as well as patient‐perceived quality of life enhancements, thereby providing a more complete perspective compared to analyses focusing solely on clinical outcomes. Proportions of patients achieving 75% improvement in Psoriasis Area and Severity Index (PASI 75), PASI 90, PASI 100, minimally important difference in Dermatology Life Quality Index (DLQI MID), DLQI 0/1, and Patient Global Assessment (PtGA) MID at 12 weeks were evaluated. The number needed to treat (NNT) and incremental cost per responder (ICPR) were computed for treatments relative to acitretin. A total of 1916 patients with chronic plaque psoriasis were analyzed, with 240 patients on acitretin, 459 on methotrexate, 391 on phototherapy, 64 on adalimumab, 164 on ustekinumab, 97 on guselkumab, 298 on secukinumab, and 203 on ixekizumab. At 12 weeks, patients on methotrexate (adjusted relative risk [RR], 2.03 [95% CI, 1.66–2.48]), phototherapy (RR, 2.01 [95% CI, 1.64–2.46]), adalimumab (RR, 2.22 [95% CI, 1.66–2.96]), ustekinumab (RR, 2.86 [95% CI, 2.27–3.62]), guselkumab (RR, 3.34 [95% CI, 2.54–4.38]), secukinumab (RR, 3.38 [95% CI, 2.74–4.16]), and ixekizumab (RR, 3.59 [95% CI, 2.88–4.47]) were more likely to achieve PASI 75 versus patients on acitretin. Comparable rankings were observed for PASI 90, PASI 100, DLQI MID, DLQI 0/1, and PtGA MID. Additionally, methotrexate and phototherapy demonstrated numerically lower ICPR values compared to other evaluated treatments, while ixekizumab exhibited the lowest ICPR among the biologics. Overall, our study indicated that ixekizumab, secukinumab, guselkumab, and ustekinumab demonstrated superior effectiveness compared to other therapies at 12 weeks. Methotrexate and phototherapy offered the best cost‐effectiveness, while ixekizumab led in cost‐effectiveness among biologics.


  • Open Access

    Modified human skin cell isolation protocol and its influence on keratinocyte and melanocyte culture

    by Zhi Liu, Shunxin Jin, Dapeng Cheng, Hao Chen, Yuxiang Wang, Chao Ji, Zhenzhen Yan, Xiao Fang, Shichu Xiao, Xinling Bi


  • Open Access

    FANCI serve as a prognostic biomarker correlated with immune infiltrates in skin cutaneous melanoma

    by Zhenguo Cai, Yanjuan Duan, Wen Li, Zhuohang Liu, Zijun Gong, Sheng Hong, Xu He, Xinyang Xuanyuan, Youdong Chen, Xinling Bi, et al.

    Background: As a member of tumor, Skin cutaneous melanoma (SKCM) poses a serious threat to people’s health because of its strong malignancy. Unfortunately, effective treatment methods for SKCM remain lacking. FANCI plays a vital role in the occurrence and metastasis of various tumor types. However, its regulatory role in SKCM is unclear. The purpose of this study was to explore the association of FANCI with SKCM.Methods: This study investigated the expression of FANCI in GSE46517, GSE15605, and GSE114445 from the Gene Expression Omnibus database and The Cancer Genome Atlas (TCGA)-SKCM datasets using the package “limma” or “DESeq2” in R environment and also investigated the prognostic significance of FANCI by utilizing the GEPIA database. Additionally, our research made use of real-time quantitative polymerase chain reaction (RT-qPCR) and immunohistochemical (IHC) staining to verify FANCI expression between SKCM and normal tissues and developed the knockdown of FANCI in A375 and A875 cells to further analyze the function of FANCI. Finally, this study analyzed the correlation of FANCI and tumor-infiltrating immune cells by CIBERSORT, ESTIMATE, and ssGSEA algorithms.Results: The FANCI level was increasing in SKCM tissues from GSE46517, GSE15605, GSE114445, and TCGA-SKCM. However, high FANCI expression correlated with poor overall survival. The RT-qPCR and IHC confirmed the accuracy of bioinformatics. Knocking down FANCI suppresses A375 and A875 cell proliferation, migration, and invasion. FANCI could be involved in the immunological milieu of SKCM by regulating immune responses and infiltrating numerous immune cells, particularly neutrophils, CD8+ T cells, and B cells. Furthermore, patients with SKCM who have a high FANCI expression level are reported to exhibit immunosuppression, whereas those with a low FANCI expression level are more likely to experience positive outcomes from immunotherapy.Conclusions: The increased FANCI expression in SKCM can be a prognostic biomarker. Knockdown FANCI can reduce the occurrence and progression of SKCM. The FANCI expression provides a foundation for predicting the immune status and treatment of SKCM.


  • Open Access

    New insights into inflammatory memory of epidermal stem cells

    by Dapeng Cheng, Xiaochen Zhu, Shaochen Yan, Linli Shi, Zhi Liu, Xin Zhou, Xinling Bi

    Inflammatory memory, as one form of innate immune memory, has a wide range of manifestations, and its occurrence is related to cell epigenetic modification or metabolic transformation. When re-encountering similar stimuli, executing cells with inflammatory memory function show enhanced or tolerated inflammatory response. Studies have identified that not only hematopoietic stem cells and fibroblasts have immune memory effects, but also stem cells from various barrier epithelial tissues generate and maintain inflammatory memory. Epidermal stem cells, especially hair follicle stem cells, play an essential role in wound healing, immune-related skin diseases, and skin cancer development. In recent years, it has been found that epidermal stem cells from hair follicle can remember the inflammatory response and implement a more rapid response to subsequent stimuli. This review updates the advances of inflammatory memory and focuses on its mechanisms in epidermal stem cells. We are finally looking forward to further research on inflammatory memory, which will allow for the development of precise strategies to manipulate host responses to infection, injury, and inflammatory skin disease.


  • Open Access

    First case report of complete paternal isodisomy of chromosome 10 harbouring a novel variant in COL17A1 that causes junctional epidermolysis bullosa intermediate

    by Yao Wang, Dong Yu, Wei Wei, Hao Zheng, Ming-Hua Liu, Long Ma, Li-Na Qin, Neng-Zhuang Wang, Jia-Xi Li, Jin-Jiang Wang, et al.

    Background: Uniparental disomy (UPD) is a condition in which both chromosomes are inherited from the same parent, except for imprinting disorders. Uniparental isodisomy (UPiD) may result in a homozygous variant contributing to an autosomal recessive disorder in the offspring of a heterozygous carrier. Junctional epidermolysis bullosa intermediate (JEB intermediate) is an autosomal recessive inherited disease that is associated with a series of gene variants, including those of COL17A1. Case presentation: We report the first case of complete paternal UPiD of chromosome 10 harbouring a novel homozygous variant in COL17A1: c.1880(exon23)delG (p.G627Afs*56). This variant led to the clinical phenotype of junctional epidermolysis bullosa intermediate in a 5-year-old child. Trio-whole exome sequencing (Trio-WES) and in silico data analysis were used for variant identification, Sanger sequencing was performed for variant validation, and pathological examination was performed as the gold standard for phenotype confirmation. Conclusions: We recommend the use of WES as a first-tier test for the diagnosis of epidermolysis bullosa, especially for paediatric patients. Moreover, UPD events should be detected and analysed routinely through WES data in the future.


  • Open Access

    Secondary Generalized Cutaneous Mucinosis Developed During Etanercept Treatment in a Patient with Psoriasis

    by Xin Zhou, David Mubanga, Zhuo Chen, Xinling Bi

    Cutaneous mucinosis is a rare disease that manifests as an excessive accumulation of mucin in the skin that forms waxy papules or plaques. We report a case of a 44-year-old male psoriatic patient who developed generalized cutaneous mucinosis after 11 months of biological treatment. The patient had a history of psoriasis for 20 years and had been treated with narrow-band UVB phototherapy, methotrexate, or acitretin intermittently. He was started on etanercept after he was diagnosed with psoriatic arthritis, and 11 months later, he complained of swelling in his extremities and myxoid cysts on his fingers. Etanercept was then discontinued due to loss of efficacy and widespread skin lesions. However, the lesions subsided spontaneously after 6 months without specific systemic treatment.